Financial Performance - Net profit attributable to shareholders decreased by 5.40% to CNY 439,096,655.30 year-on-year[4] - Operating revenue decreased by 4.55% to CNY 1,916,276,244.30 compared to the same period last year[4] - Basic earnings per share decreased by 13.33% to CNY 0.494[4] - The company reported a significant decrease in credit impairment losses, with a change of -106.86% to ¥810,895.31 from -¥11,822,497.33, due to a reduction in accounts receivable[10] - The net profit for Q1 2021 was CNY 439,096,655.30, a decrease from CNY 464,173,082.28 in Q1 2020, representing a decline of approximately 5.7%[21] - The total profit for Q1 2021 was CNY 505,204,318.51, down from CNY 543,317,661.60 in the same period last year, indicating a decrease of about 7%[21] - The basic earnings per share for Q1 2021 was CNY 0.494, compared to CNY 0.570 in Q1 2020, reflecting a decline of approximately 13.3%[21] Asset and Liability Overview - Total assets increased by 5.85% to CNY 11,131,266,766.56 compared to the end of the previous year[4] - The company's total assets reached ¥11,131,266,766.56, up from ¥10,515,832,622.85, indicating growth in overall asset base[14] - The total liabilities amounted to ¥2,928,966,620.46, compared to ¥2,752,651,384.65, reflecting an increase in financial obligations[16] - The company's cash and cash equivalents stood at ¥3,650,827,746.53, up from ¥2,959,156,601.04, showing improved liquidity[12] - The company reported total liabilities reached CNY 2,752,651,384.65, with current liabilities totaling CNY 1,967,009,962.34 and non-current liabilities at CNY 785,641,422.31[33] Shareholder Information - The number of shareholders reached 101,484 at the end of the reporting period[7] - The largest shareholder, Jiangsu Jichuan Holding Group Co., Ltd., holds 46.92% of the shares[7] - Shareholders' equity totaled CNY 10,425,717,806.80 in Q1 2021, down from CNY 10,431,222,987.91 in Q1 2020, reflecting a minor decrease in equity value[19] Cash Flow Analysis - Cash flow from operating activities increased by 3.37% to CNY 728,435,343.00[4] - The cash inflow from operating activities in Q1 2021 was CNY 2,337,279,780.54, compared to CNY 2,289,997,899.79 in Q1 2020, reflecting an increase of approximately 2.1%[26] - The net cash flow from operating activities for Q1 2021 was approximately ¥728.44 million, an increase from ¥704.71 million in Q1 2020, reflecting a growth of about 3.5%[29] - The total cash inflow from investment activities was approximately ¥784.69 million, significantly higher than ¥191.77 million in the same period last year, indicating a year-over-year increase of over 309%[29] - The cash paid to employees was approximately ¥291.13 million, compared to ¥270.39 million in the same period last year, marking an increase of about 7.6%[29] Research and Development - R&D expenses rose by 43.24% to ¥78,533,675.61 from ¥54,826,228.53, primarily due to an increase in personnel and salaries[10] - Research and development expenses increased to CNY 78,533,675.61 in Q1 2021, compared to CNY 54,826,228.53 in Q1 2020, indicating a focus on innovation[20] - The company’s management indicated ongoing efforts in research and development, although specific new products or technologies were not detailed in the report[25] Financial Standards and Adjustments - The company implemented a new leasing standard starting from January 1, 2021, resulting in a 100% increase in right-of-use assets[9] - The company implemented new leasing standards effective January 1, 2021, resulting in adjustments to financial statements[38] - The company's non-current liabilities due within one year increased by 306.16% to ¥5,053,611.57 from ¥1,244,231.01 due to increased interest on convertible bonds and the implementation of new leasing standards[10]
济川药业(600566) - 2021 Q1 - 季度财报